Related Experiment Video
Updated: Jun 23, 2025
12:55
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
21.4K
Immunotherapy for pediatric low-grade gliomas.
Ian F Pollack1,2,3, James Felker4,5,6, Stephen C Frederico5,6
1Department of Neurosurgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. ian.pollack@chp.edu.
Summary
Pediatric low-grade gliomas (pLGGs) are common childhood brain tumors. While MAPK pathway inhibitors show promise, immunotherapy offers a potential alternative for long-term disease control, possibly reducing the need for continuous treatment.
Area of Science:
- Pediatric neuro-oncology
- Cancer signaling pathways
- Immunotherapy in pediatric cancers
Background:
- Pediatric low-grade gliomas (pLGGs) are the most frequent pediatric brain tumors.
- Surgical resection is often incomplete due to tumor location or diffuse infiltration.
- Conventional chemotherapy offers suboptimal long-term control for unresectable pLGGs.
Purpose of the Study:
- To review the role of immunotherapy in managing pediatric low-grade gliomas.
- To discuss current treatment options and future directions for pLGGs.
- To highlight the potential of immunotherapy to improve long-term disease control.
Main Methods:
- Review of existing literature on pLGG treatment strategies.
- Analysis of the efficacy of MAPK pathway inhibitors.
- Exploration of immunotherapy as a therapeutic option for pLGGs.
Main Results:
- Constitutive activation of the MAPK pathway is common in pLGGs.
- Targeting the MAPK pathway shows efficacy but often requires long-term treatment.
- Immunotherapy is emerging as a promising strategy to delay or avoid continuous treatment.
Conclusions:
- Immunotherapy represents a novel approach for pediatric low-grade gliomas.
- Further research is needed to optimize immunotherapy protocols for pLGGs.
- Immunotherapy may offer a way to achieve durable disease control with potentially less long-term toxicity.
